HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%

Authors:
Gregory L Price Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Gregory L Price in
Current site
Google Scholar
PubMed
Close
 MPH
,
Frank N Cinfio Medical Decision Modeling (MDM) Inc., Indianapolis, IN

Search for other papers by Frank N Cinfio in
Current site
Google Scholar
PubMed
Close
 BS
,
Pamela A Martin Medical Decision Modeling (MDM) Inc., Indianapolis, IN

Search for other papers by Pamela A Martin in
Current site
Google Scholar
PubMed
Close
 PhD
,
Alexandra S Vitko Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Alexandra S Vitko in
Current site
Google Scholar
PubMed
Close
 PhD
,
Mark E Boye Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Mark E Boye in
Current site
Google Scholar
PubMed
Close
 PhD
,
Angelo DeLuca Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Angelo DeLuca in
Current site
Google Scholar
PubMed
Close
 PharmD
,
Christopher A Bly Medical Decision Modeling (MDM) Inc., Indianapolis, IN

Search for other papers by Christopher A Bly in
Current site
Google Scholar
PubMed
Close
 BA
,
Chelsea Manion Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Chelsea Manion in
Current site
Google Scholar
PubMed
Close
 PharmD
, and
Jacqueline Brown Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Search for other papers by Jacqueline Brown in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

Corresponding Author: Gregory L. Price, MPH
  • Collapse
  • Expand